| 查看: 4578 | 回复: 178 | |||
| 【有奖交流】积极回复本帖子，参与交流，就有机会分得作者 geniusma 的 22 个金币 ，回帖就立即获得 1 个金币，每人有 1 次机会 | |||
[交流]
Call for Papers: SCI杂志 PPAR Research (IF: 2.93) Special Issue约稿!
|
|||
|
SCI杂志PPAR Research (IF: 2.93)特刊PPARs and Their Coactivators in Obesity and Metabolic Disease 约稿啦！ 本人和美国团队受邀作为special issue编辑开一期特刊。 杂志这几年影响因子稳步上升，今年很可能过3分！PPAR及其辅激活蛋白在代谢相关疾病，包括肿瘤中的机制和治疗均可！ Open Access期刊仁者见仁，智者见智，接近3分的PPAR Research (中科院三区) 质量还是不错的。 https://www.hindawi.com/journals/PPAR/si/812927/cfp/ 欢迎投稿！欢迎转发！ PPARs and Their Coactivators in Obesity and Metabolic Disease Call for Papers Peroxisome proliferator-activated receptors (PPARs) are a subfamily of ligand-inducible nuclear hormone receptors including PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3), which have distinct tissue distribution and specific functions in response to their agonists. PPARs have been recognized as master regulators of a number of physiological processes in multiple organs and cell types, participating in cellular differentiation, development, carbohydrate and lipid metabolism, energy homeostasis, tumorigenesis, and inflammation. Given that PPARs are known to play central functions in metabolic homeostasis, highly effective PPAR agonists have been developed and are widely used for the treatment of chronic metabolic diseases. Upon specific ligand-binding, PPARs heterodimerize with the retinoid X receptor (RXR) and bind to the peroxisome proliferator responsive element (PPRE) on target genes. Importantly, the transcriptional activation of specific target genes set in motion by liganded PPARs is also determined by a number of coactivators that partner with PPARs in a tissue- and cell type-specific manner. Three major categories of PPAR coactivators have been identified: (1) those with chromatin remodeling effects, such as those carrying histone acetyltransferase (HAT) or methyltransferase activity (i.e., members of the p160/SRC family); (2) anchoring coactivators, which serve as linkers between cofactor complexes and the basal transcriptional machinery (i.e., members of the mediator complex); (3) coactivators without intrinsic enzymatic activity which function by providing a scaffold to aggregate large transcriptional complexes on tissue specific target genes: these cofactors include PGC1 family members among others. These coactivators have also been shown to be recruited in response to ligand/agonist activation to a number of nuclear receptors and transcriptional factors in addition to PPARs. As one of the most serious public health problems of the 21st century, obesity is mainly caused by the combination of excessive caloric intake, sedentary lifestyle, and genetic susceptibility. Obesity is the leading risk factor for many physical disorders commonly known as the metabolic disease/syndrome which includes but is not limited to type 2 diabetes, hypertension, hyperlipidemia, cardiovascular diseases, hepatic steatosis, and certain types of cancer ultimately reducing life expectancy. Thus, understanding the molecular basis of PPARs and coactivator functions in controlling the expression of selective gene programs may be helpful for the development of possible strategies to prevent/treat obesity and metabolic comorbidities. We invite investigators to submit original research articles and review articles that aim to increase our knowledge on the molecular basis of the effects of PPARs and of cofactors on metabolism and on energy homeostasis, in a PPAR dependent or independent manner. Studies describing strategies targeting PPARs and cofactors to prevent/treat obesity and metabolic diseases are also highly welcomed. Potential topics include but are not limited to the following: Role of PPARs and cofactors (a) in energy homeostasis and metabolic disease, including obesity, type 2 diabetes, hypertension, hyperlipidemia, cardiovascular diseases, hepatic steatosis, and chronic inflammation; (b) in certain types of cancer and aging-related diseases; (c) in adipocyte biology Role of noncoding RNAs in the regulation of PPARs and cofactors in homeostasis and metabolic disease Epigenetic modifications of PPARs and cofactors affecting homeostasis and metabolic disease Mechanisms of preferential recruitment of cofactors to PPARs to specify lipid storage and thermogenic gene programs, under certain physiological conditions New PPARs ligands and/or cofactors agonists as therapeutic agents for metabolic diseases Novel strategies targeting PPARs and cofactors for preventing/treating metabolic disease Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/ppar/comd/. Manuscript Due Friday, 2 June 2017 First Round of Reviews Friday, 25 August 2017 Publication Date Friday, 20 October 2017 Lead Guest Editor Xinran Ma, East China Normal University, Shanghai, China Guest Editors Lingyan Xu, East China Normal University, Shanghai, China Elisabetta Mueller, New York University, New York, USA |
回复此楼» 猜你喜欢
关于filecode，很负责任的告诉大家
已经有7人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
关于豆爷回答的JTJC与%2F数量
已经有7人回复
-
2026国自然放榜时间
已经有3人回复
-
国基金的申报应该改成非等额制，评价高的钱多评价低的钱少，但是增加资助率
已经有7人回复
-
好奇怪的filecode
已经有4人回复
-
售SCI文章，我:8O5.5.1.O.54,科目齐全,可+急
已经有4人回复
-
售SCI一区T0P文章，我:8.O.55.1.O54,科目全,可伽急
已经有4人回复
-
售SCI文章，我:8O.5.5.1O.54,科目全,可十急
已经有4人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急
已经有5人回复
» 抢金币啦！回帖就可以得到:
-
祈福
+5/520
-
中科院招聘博士后及科研助理
+2/220
-
别研究filecode了，祝都有一个好结果：）
+2/94
-
3-丁烯-1-醇（CAS：627-27-0）
+1/87
-
3,4-二(三甲基硅氧基)-1-丁烯（CAS：89543-84-0）
+1/87
-
丁烯二醇（CAS: 497-06-3）
+1/86
-
1,2-双(三甲基硅氧基)苯（CAS：5075-52-5）
+1/85
-
十二烷基溴化吡啶（CAS：104-73-4）
+1/84
-
招聘机械领域专利代理人
+1/80
-
哈尔滨工业大学郑州高等研究院查正宝研究员招收博士/硕士
+1/32
-
哈工大（深圳）何自开团队诚招化学工程与技术专业博士生
+1/27
-
中山大学计算数学方向招2027届考核制博士生
+1/16
-
国家纳米科学中心段鹏飞课题组招收2027年入学博士研究生
+1/4
-
香港理工大学殷骏课题组诚聘1 名博士后以及2 名博士生
+1/4
-
COMSOL鼓泡塔模拟液相消失求助
+1/4
-
高弯曲强度玻璃制品的特殊加工工艺
+1/3
-
北理工集成电路杰青团队 | 诚招科助理
+1/2
-
北理工集成电路杰青团队 | 诚招科助理
+1/2
-
POSTDOCTORAL POSITION in Structural Virology at the University of Minnesota
+1/1
-
上海交通大学化学化工学院张智涛课题组诚聘博士后
+1/1
9楼2016-12-27 21:25:23
32楼2016-12-27 22:22:53
简单回复
2016-12-27 20:55
回复
JOEF3楼
2016-12-27 21:01
回复
geniusma(金币+1): 谢谢参与
2016-12-27 21:04
回复
geniusma(金币+1): 谢谢参与
2016-12-27 21:17
回复
2016-12-27 21:21
回复
geniusma(金币+1): 谢谢参与
2016-12-27 21:22
回复
geniusma(金币+1): 谢谢参与
tan9148楼
2016-12-27 21:23
回复
geniusma(金币+1): 谢谢参与
paperhunter10楼
2016-12-27 21:25
回复
geniusma(金币+1): 谢谢参与
103062354311楼
2016-12-27 21:28
回复
geniusma(金币+1): 谢谢参与
多啦C梦060112楼
2016-12-27 21:31
回复
geniusma(金币+1): 谢谢参与
chejiacun13楼
2016-12-27 21:33
回复
geniusma(金币+1): 谢谢参与
lvluohua92914楼
2016-12-27 21:37
回复
geniusma(金币+1): 谢谢参与
三八洲15楼
2016-12-27 21:41
回复
geniusma(金币+1): 谢谢参与
icebergwu16楼
2016-12-27 21:44
回复
geniusma(金币+1): 谢谢参与
zuiaixuexi17楼
2016-12-27 21:45
回复
geniusma(金币+1): 谢谢参与
好
超级老快18楼
2016-12-27 21:47
回复
geniusma(金币+1): 谢谢参与
。 发自小木虫Android客户端
yexuqing19楼
2016-12-27 21:47
回复
geniusma(金币+1): 谢谢参与
祝福 发自小木虫Android客户端
longwave20楼
2016-12-27 21:50
回复
geniusma(金币+1): 谢谢参与
祝福 发自小木虫Android客户端
gengxin6021楼
2016-12-27 21:52
回复
geniusma(金币+1): 谢谢参与
吸血人狼城22楼
2016-12-27 21:56
回复
假大空23楼
2016-12-27 21:57
回复
geniusma(金币+1): 谢谢参与
顶
sunjialin12324楼
2016-12-27 21:57
回复
geniusma(金币+1): 谢谢参与
。 发自小木虫Android客户端
bj200898925楼
2016-12-27 22:02
回复
geniusma(金币+1): 谢谢参与
腿哥帅26楼
2016-12-27 22:06
回复
纳米材料75327楼
2016-12-27 22:07
回复
geniusma(金币+1): 谢谢参与
qwertyupoiuy28楼
2016-12-27 22:07
回复
geniusma(金币+1): 谢谢参与
！ 发自小木虫Android客户端
ajingne129楼
2016-12-27 22:13
回复
小木木头嘎达30楼
2016-12-27 22:14
回复
西北狼东北虎31楼
2016-12-27 22:17
回复
落花剑雨33楼
2016-12-27 22:26
回复
geniusma(金币+1): 谢谢参与
鱼儿123434楼
2016-12-27 22:27
回复
geniusma(金币+1): 谢谢参与
。 发自小木虫Android客户端
34868356935楼
2016-12-27 22:28
回复
hzk2zd36楼
2016-12-27 22:32
回复
geniusma(金币+1): 谢谢参与
牛 发自小木虫Android客户端
nono200937楼
2016-12-27 22:33
回复
geniusma(金币+1): 谢谢参与
`
syhorchid38楼
2016-12-27 22:36
回复
geniusma(金币+1): 谢谢参与
spc0839楼
2016-12-27 22:38
回复
geniusma(金币+1): 谢谢参与
dsctg40楼
2016-12-27 22:39
回复
geniusma(金币+1): 谢谢参与
sunjump41楼
2016-12-27 22:49
回复
geniusma(金币+1): 谢谢参与
vox70742楼
2016-12-27 22:59
回复
geniusma(金币+1): 谢谢参与
huzhang0143楼
2016-12-27 23:11
回复
geniusma(金币+1): 谢谢参与
OK 发自小木虫IOS客户端
xjd201444楼
2016-12-27 23:27
回复
1839482278645楼
2016-12-27 23:35
回复
chentao46楼
2016-12-27 23:41
回复
geniusma(金币+1): 谢谢参与
wtbccq50547楼
2016-12-27 23:43
回复
geniusma(金币+1): 谢谢参与
tableman48楼
2016-12-27 23:45
回复
geniusma(金币+1): 谢谢参与
祝福了。
nbjiuxu49楼
2016-12-27 23:55
回复
LifePursuit50楼
2016-12-27 23:56
回复
geniusma(金币+1): 谢谢参与
一 发自小木虫IOS客户端
